drugset / Trial / NCT01924299

A Study of Baricitinib When Administered With Ketoconazole or Fluconazole in Healthy Participants

NCT01924299

Phase 1 Completed 36 enrolled Eli Lilly and Company
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The main purpose of this study is to look at the effect of ketoconazole and fluconazole on how much baricitinib gets into the blood stream. The study will also look at the tolerability of baricitinib and ketoconazole when given together and the tolerability of baricitinib and fluconazole when given together. Participants will be recruited into 1 of 2 treatment groups (Group A or Group B). Each treatment group will participate in 2 study periods. Participants will take baricitinib alone in 1 period and baricitinib with either ketoconazole or fluconazole in the other period. This study will last approximately 7 weeks.

Timeline

Start
2013-08
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Baricitinib Small molecule 10 mg Oral
Subject Fluconazole Small molecule 200 mg Oral
Subject Ketoconazole Small molecule 400 mg Oral

Indications

No indication recorded.